Modification of ventricular fibrillation thresholds after sympatholytic drugs in the dog.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000494:pharmacology; D003864:Depression, Chemical; D004285:Dogs; D004558:Electric Stimulation; D004983:Ethanolamines / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology; D006321:Heart / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects*; D011433:Propranolol / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D012110:Reserpine / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology*; D014693:Ventricular Fibrillation / Q000503:physiopathology / Q000517:prevention & control*
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D004983:Ethanolamines; D011941:Receptors, Adrenergic; D013565:Sympatholytics; D012110:Reserpine; D011433:Propranolol; D006145:Guanethidine